Inhibikase Therapeutics Interest Expense 2011-2026 | IKT

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Inhibikase Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
3.72 M	1.07 M	1.06 M	74.5 K	-19.9 K	29.4 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.72 M	-19.9 K	988 K

Quarterly Interest Expense Inhibikase Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
838 K	917 K	919 K	-	49.4 K	90.9 K	133 K	-	174 K	424 K	237 K	-	18.5 K	5	-5	-	157	7.81 K	11.8 K	-	6.89 K	7.95 K	7.42 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
919 K	-5	214 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Verastem VSTM	1.14 M	$ 5.04	-4.73 %	$ 349 M	USA
VistaGen Therapeutics VTGN	5 K	$ 0.57	-5.87 %	$ 17.6 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Adaptive Biotechnologies Corporation ADPT	11.8 M	$ 12.41	-11.1 %	$ 1.88 B	USA
Xenon Pharmaceuticals XENE	484 K	$ 54.48	-1.89 %	$ 4.24 B	Canada
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Enochian Biosciences ENOB	122 K	-	-	$ 40.5 M	USA
Summit Therapeutics SMMT	-53 K	$ 16.58	-3.94 %	$ 12.4 B	Britain
Alnylam Pharmaceuticals ALNY	5.2 M	$ 317.36	-3.29 %	$ 41.6 B	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.29	-3.6 %	$ 822 M	Canada
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Fusion Pharmaceuticals FUSN	762 K	-	-	$ 1.41 B	Canada
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 19.01	-2.66 %	$ 889 M	USA
Gritstone Oncology GRTS	4.04 M	-	0.42 %	$ 213 M	USA
ACADIA Pharmaceuticals ACAD	1.82 M	$ 20.75	-3.35 %	$ 3.44 B	USA
Aligos Therapeutics ALGS	2.2 M	$ 6.66	-5.4 %	$ 65.8 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Alkermes plc ALKS	4.47 M	$ 29.39	-1.77 %	$ 4.84 B	Irlanda
Cabaletta Bio CABA	2 M	$ 2.68	-4.96 %	$ 269 M	USA
AbbVie ABBV	2.89 B	$ 209.4	-0.81 %	$ 370 B	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.27	-2.39 %	$ 977 M	Canada
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Athira Pharma ATHA	3.96 M	-	-	$ 269 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA